Abstract
Purpose: To clarify the epidemiological, clinical, and therapeutic features of patients with severe COVID-19.
Methods: In this study, we enrolled 681 patients with confirmed cases of severe COVID-19. The epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected.
Results: The median age of the study participants was 65 years, 53.2% were male, and 104 (15.3%) died. Age, Neutrophil-To-Lymphocyte Ratio (NLR), acute myocardial injury, and levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and CD3 T cells counts were independently associated with death, while arbidol and ribavirin were protective from death. The combination of NLR and acute myocardial injury on admission (AUC = 0.914) predicted mortality better than NLR, CRP, LDH, and acute myocardial injury. There were 312 (45.8%) patients with cardiovascular disease, of whom 23.4% died. β-blockers, ACEI/ARB, arbidol, and ribavirin might have a beneficial effect for severe COVID-19 patients with cardiovascular disease.
Conclusion: The combination of NLR and acute myocardial injury on admission was highly predictive of mortality and survival. Clinicians should adopt more aggressive strategies for patients with a high NLR (>6.66) combined with myocardial injury. β-blockers and ACEI/ARB, as well as arbidol and ribavirin, were effective in COVID-19 patients with cardiovascular disease.
Keywords: COVID-19; Cardiovascular disease; Clinical characteristics; SARS-CoV-2; Treatments.
【저자키워드】 COVID-19, SARS-CoV-2, Clinical characteristics, cardiovascular disease, treatments, 【초록키워드】 Treatment, Arbidol, Mortality, severe COVID-19, Clinical characteristics, T cells, neutrophil, LDH, C-reactive protein, cardiovascular disease, CRP, outcome, lactate dehydrogenase, ribavirin, Laboratory, cardiovascular, Neutrophil-to-lymphocyte ratio, lymphocyte, T cell, myocardial injury, survival, clinical, therapeutic, male, Patient, death, epidemiological, Admission, COVID-19 patients, Protective, ACEi, NLR, Lactate, Combination, COVID-19 patient, AUC, on admission, Predictive, confirmed case, confirmed cases, median age, Study participants, severe COVID-19 patients, blockers, ACEi/ARB, CD3, feature, effective, β-blockers, enrolled, predicted, collected, died, Ratio, study participant, severe COVID-19 patient, β-blocker, 【제목키워드】 outcome, China, Characteristics, Severe case, with COVID-19,